Reata Pharmaceuticals Says Ongoing Trials In Patients With Pulmonary Arterial Hypertension Stopped Due To High Risk Of COVID-19 To These Patients

Reata Pharmaceuticals Says Ongoing Trials In Patients With Pulmonary Arterial Hypertension Stopped Due To High Risk Of COVID-19 To These Patients

Submitted by admin on March 30, 2020 - 8:18pm
Source: 
Reuters
News Tags: 
Reata Pharmaceuticals
PAH
clinical trials
COVID-19
Headline: 
Reata Pharmaceuticals Says Ongoing Trials In Patients With Pulmonary Arterial Hypertension Stopped Due To High Risk Of COVID-19 To These Patients
snippet: 

Ongoing clinical trials in patients with pulmonary arterial hypertension stopped due to high risk of COVID-19 to these patients.

Do Not Allow Advertisers to Use My Personal information